Monitor for IND/CTA filing in 2H 2027 and any non-dilutive funding awards. Cash runway is limited; additional financing likely needed before clinical milestones.
How the stock moved after the report
NEUTRAL VIEWSTOCK AT ENTRY AT T+5- T+0 · Nov 3 $1.11entry
- T+1 · 13d ago +2.70%α +1.05% · $1.14
- T+5 · 7d ago 0.00%α +0.59% · $1.11
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Decoy Therapeutics reported Q3 2026 cash of $8.1M and provided a pipeline update. The lead pan-coronavirus program is expected to file a CTA/IND in 2H 2027, with once-weekly dosing potential shown in preclinical studies. No revenue or EPS was reported; the company remains pre-revenue with a cash runway that may fund operations into 2027.
Key Facts
- Cash on balance sheet was $8.1 million at September 30, 2026, including ~$2.5M restricted Gates Foundation grant funding.
- Lead pan-coronavirus program expected to file CTA/IND in 2H 2027.
- Optimized lead candidate showed potential for once-weekly dosing in preclinical studies.
- Pan-filovirus program targeting Ebola, Marburg and related viruses is being explored.
- Company is pursuing non-dilutive funding from U.S. government and military agencies.
- 2,385,282 shares of common stock outstanding as of September 30, 2026.
- No revenue or EPS reported; company is pre-revenue.
Financial Impact
Cash burn rate not disclosed; $8.1M cash on hand with no revenue. Market cap ~$3M.
Risk Factors
- Cash balance of $8.1M may not be sufficient to fund operations through IND filing without additional financing.
- Preclinical stage; no approved products or revenue.
- Reliance on non-dilutive funding and strategic collaborations that may not materialize.
- Forward-looking statements subject to significant regulatory and development risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3394089 |
Track record
13 reports on DCOY
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +67.67% at T+60 after the Jun 29, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago S-3 Bearish 6/10 Entry $1.02 Now $0.9010 +11.66% settles Dec 15
- Nov 3, 202613d ago Press Release Neutral 3/10 Viewing Entry $1.11 Now $0.9010 −18.83% settles Dec 2
- Oct 19, 202629d ago EFFECT Neutral 4/10 Entry $1.17 to $0.9752 Now $0.9010 −22.99% ▼ −16.65% −13.19% vs SPY
- Oct 7, 20265w ago S-1 Bearish 6/10 Entry $1.52 to $1.14 Now $0.9010 +40.72% ▲ +25.00% +19.71% vs SPY
- Sep 23, 20267w ago 8-K Bearish 6/10 Entry $3.11 to $1.03 Now $0.9010 +71.03% ▲ +66.88% +66.46% vs SPY
- Aug 4, 202614w ago DEFA14A Neutral 3/10 Entry $4.19 to $2.98 Now $0.9010 −78.50% ▼ −28.88% −28.28% vs SPY
- Jul 20, 202617w ago EFFECT Neutral 4/10 Entry $5.31 to $3.52 Now $0.9010 −83.02% ▼ −33.65% −37.77% vs SPY
- Jun 29, 202620w ago 8-K Bearish 7/10 Entry $9.59 to $5.04 Now $0.9010 +90.60% ▲ +47.45% +47.17% vs SPY
- Jun 25, 202620w ago EFFECT Neutral 5/10 Entry $5.92 to $4.94 Now $0.9010 −84.78% ▼ −16.53% −17.05% vs SPY
- Jun 4, 202623w ago DEFA14A Neutral 3/10 Entry $6.71 to $7.31 Now $0.9010 −86.57% ▲ +8.94% +10.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers